皮洛卢里亚的微量营养素治疗:对患者接受度的回顾性分析
Lena Zingg1, Elena Pavicic2,3, Norman Bitterlich4
1Faculty of Medicine, University of Bern, Bern, Switzerland.
Archives of gynecology and obstetrics
|January 6, 2026
概括
患有有争议的代谢状况 - - 铁尿症的患者报告说,微量营养素治疗的接受度很高. 虽然耐受性很好,但其感知有效性是温和的,这需要进一步研究热尿和微量营养素的有效性.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
- 妇科卫生保健 妇科卫生保健
背景情况:
- 皮洛卢里亚是一种有争议的代谢状况,在传统医学中缺乏强有力的经验证据.
- 微量营养素疗法经常被用于补充医学中的pyrroluria.
- 患者接受这种疗法仍然在很大程度上未经记录.
研究的目的:
- 为了评估患者接受用于pyrroluria的处方微量营养素治疗.
- 在临床环境中记录患者对微量营养素治疗的经验.
- 不是为了验证Pyrroluria,而是为了评估治疗的坚持.
主要方法:
- 在伯尔尼大学医院进行的回顾性队列研究 (2022/2023).
- 纳入标准:检测出pyrroluria阳性并接受微量营养素治疗的患者.
- 主要结局:通过ACCEPT©问卷测量整体治疗接受度.
主要成果:
- 微量营养素治疗的总体接受度很高 (平均得分为74/100).
- 治疗在副作用 (85/100),长期使用 (85/100) 和治疗方案 (84/100) 方面得到了很好的接受.
- 感知疗效得分为63/100,没有达到统计学意义 (p=0.7).
结论:
- 微量营养素疗法被耐受性很好,并且被热尿患者接受.
- 该疗法显示出作为低风险辅助干预的潜力.
- 进一步的安慰剂对照试验是必要的,以验证pyrroluria和微量营养素的有效性.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Chronic Kidney Disease III: Interprofessional Care
333
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
Therapeutic Drug Monitoring: Affecting Factors
196
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
196
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
146
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
146

